LAS VEGAS, NV / ACCESSWIRE / December 14, 2015 / The Regenerative Medicine Market is expected to increase from US$2.6 billion in 2012 to US$6.5 billion by 2019, according to Transparency Market Research. The Regenerative Medicine Market is being driven by several technological advancements in stem cell therapy and tissue engineering.
There are a few companies that are making major strides in this arena and should be major players in this growing industry.
One that has caught our eye in particular is, Endonovo Therapeutics, Inc. (ENDV).
ENDV has filed a patent application with the United States Patent and Trademark Office (USPTO) on a large scale method of expanding blood-forming stem cells that would allow for the wide spread use of cord blood in the treatment of malignant and non-malignant hematological disorders.
ENDV is also developing two bioelectronic-based platforms for regenerative medicine. Immunotronics(TM), a non-invasive and non-implantable bioelectronic device designed to treat inflammatory conditions in vital organs, including acute organ failure; and Cytotronics(TM), a proprietary bioelectronics-based method of creating more biologically potent stem cells for cell-based therapies.
The company has put years into its research and development and is now beginning to see the fruits of their labor.
So far investors like what they see.
There are a few other biotech companies investors who are interested in ENDV might also like:
Pieris Pharmaceuticals, Inc. (PIRS), a clinical stage biopharmaceutical company, focuses on the discovery and development of Anticalin class biotherapeutics. Recently, PIRS announced a research collaboration and license agreement with Roche in cancer immunotherapy (CIT). Under the terms of the agreement, Pieris will discover, characterize and optimize Anticalin(R)-based drug candidates against an undisclosed target.
Harvard Apparatus Regenerative Technology (HART) announced that Executive Vice President and Chief Medical Officer Saverio La Francesca, MD will moderate and speak at the World Stem Cell Summit during a secession entitled "Regenerative Engineering and Bio-Materials." HART makes bioengineered organ implants for life-threatening conditions. Our technology platform is to be used to restore function in the esophagus and the airways (trachea and bronchus). HART is completing further large-animal studies to refine our technology platform with the goal of filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration in 2016, seeking to initiate clinical trials for one of our three product candidates. Thier first-generation trachea technology was used in five adult human trachea transplants approved under compassionate use exemptions, but none of our products are yet approved for marketing by a government regulatory authority.
Anavex Life Sciences (AVXL) stock popped nearly 30% after presenting some encouraging results from one of its Alzheimer's candidates. It's not uncommon for promising Alzheimer's results to move a stock. What makes the recent climb in Anavex shares so interesting is that it occurred in response to preclinical data observed in rats, from a drug that flies in the face of the prevailing thesis of how the disease could be treated. Anavex Life Sciences Corp. (AVXL) is dedicated to the development of novel drug candidates to treat central nervous system (CNS) diseases and various types of cancer. Anavex's lead drug candidates, ANAVEX 2-73 and ANAVEX PLUS, the combination of ANAVEX 2-73 and donepezil (Aricept(R)), are currently in a Phase 2a clinical trial for Alzheimer's disease. The drug combination ANAVEX PLUS produced up to 80% greater reversal of memory loss in Alzheimer's disease models versus when the drugs were used individually. ANAVEX 2-73 is an orally available drug candidate that targets sigma-1 and muscarinic receptors and successfully completed Phase 1 with a clean data profile. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease.
Giga-tronics Incorporated (GIGA) announced the release of the new Real Time Threat Emulation System. This system combines the unique multichannel fast-switching capabilities of Giga-tronics' Advanced Signal Generator hardware platform together with software based on decades of threat simulation. Giga-tronics produces instruments, subsystems and sophisticated microwave components that have broad applications in defense electronics, aeronautics and wireless telecommunications.
Legal Disclaimer
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.commay from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns, Microcapspeculators.commay be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $4,000 cash by A non-affiliate third party of ENDV.
